SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a parabolic rally driven by a low-float setup and intense short-squeeze dynamics that have captured the attention of retail traders. The community is actively debating the stock's long-term sustainability against its history of reverse splits and high borrowing costs, while many speculate about the potential for further explosive gains.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors weigh strong April year-over-year delivery growth and the launch of the Onvo L80 against ongoing delivery logistics debates and broader market volatility. Community discourse remains deeply divided between long-term holders citing the company's battery-swapping infrastructure as a massive competitive advantage and skeptics pointing to concerns over share dilution, debt, and persistent bearish price action.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk (SNDK) is experiencing a high-volatility "sell the news" reaction despite delivering a record-breaking earnings beat and issuing bullish guidance that underscores sustained AI-driven demand. While the community is debating whether this dip offers a strategic buying opportunity or confirms a long-overdue valuation cooling after a historic year-long rally, many investors are focused on the company's aggressive share buyback plan as a potential defensive catalyst.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is trending due to the announcement of a multi-million dollar milestone payment from its partnership with Boehringer Ingelheim, which has triggered heightened trader interest ahead of an R&D Day presentation. Community sentiment is mixed, with some traders optimistic about the non-dilutive capital and autoimmune pipeline potential, while others remain cautious due to concerns over potential share dilution and a pending reverse stock split.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure as investors react to a lowered bookings guidance and user engagement headwinds caused by the platform's recent safety and age-check rollout. The community remains deeply polarized, with bears focusing on the company's lack of profitability and safety concerns, while bulls point to strong free cash flow and long-term potential in the creator economy.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging after delivering a strong quarterly earnings beat, fueling investor optimism that the enterprise software sector may be bottoming out. The community is actively debating if this performance signals a broader recovery for SaaS companies or if it remains a tactical bounce amid ongoing concerns over AI-driven disruption.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is seeing heightened community discussion as investors weigh the impact of new capital partnerships against broader sector volatility and bearish sentiment surrounding fintech. While some market participants anticipate a potential short squeeze, others remain cautious as the stock grapples with macroeconomic headwinds and lingering uncertainty regarding the company's performance in a high-rate environment.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Investors are closely monitoring escalating geopolitical tensions in the Strait of Hormuz and a shifting conflict status with Iran, which is driving significant volatility and concerns over energy supply stability. The community is actively debating whether current stock market highs are sustainable in the face of these rising oil prices, Fed policy uncertainty, and mixed earnings reports.

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

iSpecimen Inc. is attracting significant community attention due to its status as a low-float stock experiencing intense volatility, with retail investors closely monitoring for a potential short squeeze amid rumors of strategic acquisitions. Community sentiment is deeply polarized, with active debates centered on the company's long-term viability, upcoming delisting concerns, and the high-conviction participation of retail traders hoping to replicate past momentum spikes.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive Inc. is trending as traders closely monitor its role as a leveraged Bitcoin proxy, with community discussion currently polarized between optimism over institutional accumulation and concerns regarding structural dilution. Investors remain focused on how the company's treasury strategy and dividend structure will perform in relation to broader Bitcoin price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rati...

Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from Chardan Capital

Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday...

Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High - Still a Buy?

Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High - Should You Buy...

Alto Neuroscience (NYSE:ANRO)  Shares Down 7.2%   - Here's Why

Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% - Time to Sell...

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b...

Alto Neuroscience (NYSE:ANRO) Trading 8.8% Higher   - Here's What Happened

Alto Neuroscience (NYSE:ANRO) Shares Up 8.8% - Here's Why...

Alto Neuroscience (NYSE:ANRO) Trading Down 6.3%  - Time to Sell?

Alto Neuroscience (NYSE:ANRO) Shares Down 6.3% - What's Next...

Q1 Earnings Estimate for ANRO Issued By HC Wainwright

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Alto Neuroscience in a research note issued on Thursday...

Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird

Robert W. Baird decreased their price target on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating on the stock in a research note on Thursday...

<ul class="summary-bullets"><li>H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience.</li><li>Baird cut Alto’s price target to $38 from $41 but said the company’s depression pipeline remains the key driver of its valuation.</li><li>Jones Research’s latest price target implies a potential 100% upside to the stock’s current price.</li></ul>Shares of Alto Neuroscience (ANRO) slid about 7% on Thursday after disappointing results from a schizophrenia treatment study prompted multiple brokerages to become more cautious on the stock.On Wednesday, Alto Neuroscience <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">said</a> its experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 Proof-of-Concept study. ALTO-101 did not show meaningful improvements in brain activity or cognitive measures compared to placebo.As a result, the biotech firm will not continue developing the drug for this use and will shift focus to other programs, including ALTO-207 for treatment-resistant depression. The company is also exploring partnership opportunities for a modified version of ALTO-101 that showed better safety and drug behavior.<h2 class="st-heading-2">Analyst Sees Pullback As Attractive Entry Point</h2>Jones Research cut Alto Neuroscience’s price target to $44 from $49, but kept a ‘Buy’ rating, according to The Fly. This implies a potential 100% upside to the stock’s current price of around $22.Analyst Justin Walsh said that while the stock’s weakness is justified, the market is underestimating Alto’s broader pipeline and sees the pullback as an attractive entry point.H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience, as the program was not a key part of its valuation, according to The Fly. The brokerage also highlighted the company’s strong cash position of $275 million, which supports its pipeline. H.C. Wainwright maintained its ‘Buy’ rating and $50 price target.Baird cut the company’s price target to $38 from $41 and maintained an ‘Outperform’ rating. Analyst Brian Skorney called the ALTO-101 Phase 2 failure disappointing, though expectations were already modest given the challenges in schizophrenia treatment. The firm said Alto’s depression pipeline remains the key driver of its valuation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/ANRO">ANRO</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user had expected a bigger drop.<stembedurl>http://stocktwits.com/Stef_DL/message/649289943</stembedurl>Year-to-date, the stock has gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/snbr-stock-on-track-to-decline-for-12th-straight-session/cZ7x67bRI8o">SNBR Stock On Track To Decline For 12th Straight Session – Retail Sees Buying Opportunity If Stock Dips Below $1</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Alto Neuroscience’s experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 study, leading to price target cuts from multiple brokerages.

Equity

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANRO News

ANROAlto Neuroscience Inc.